Complexin-1 is a presynaptic cytosolic protein encoded by CPLX1 Gene. It binds assembled SNARE Complex and controls the final step of calcium-triggered synaptic vesicle fusion.[1][2] In mechanistic terms, complexin-1 acts as both a fusion clamp and a fusion facilitator, preventing spontaneous release while enabling fast synchronized release when calcium rises.[2:1][3]
Because synaptic failure is an early and convergent event across neurodegenerative diseases, CPLX1 is relevant well beyond pure synaptic physiology. Altered complexin biology has been linked to disrupted neurotransmission in Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis, mostly as part of broader presynaptic remodeling.[4][5][6]
| Property | Value |
|---|---|
| Gene | CPLX1 Gene |
| UniProt | O75178 |
| Protein family | Complexin family |
| Approximate molecular weight | 15 kDa |
| Localization | Presynaptic cytosol near vesicle fusion sites |
| Functional module | SNARE Complex, Synaptotagmin-1 Protein, Syntaxin-1A Protein, SNAP-25 Protein |
Complexin-1 has four functional regions that map onto release control logic:[2:2][3:1]
This domain architecture enables rapid switching between restrained and permissive fusion states, matching the timing demands of millisecond neurotransmission.[1:1][2:3]
At many fast synapses, complexin-1 tightens temporal precision of vesicle fusion, reducing jitter in neurotransmitter release and preserving signal-to-noise during high-frequency activity.[1:2][3:2]
Loss of complexin function generally elevates spontaneous fusion while impairing evoked synchronous release, showing that clamping and activation are coupled features, not separate proteins doing unrelated jobs.[2:4][7]
CPLX1-dependent release control is especially relevant in cerebellar, hippocampal, and basal-ganglia circuits where timing defects can produce motor and cognitive phenotypes.[4:1][8]
In Parkinson's Disease, presynaptic stress, dopamine-terminal degeneration, and alpha-synuclein toxicity converge on release machinery. Complexin-1 is part of this vulnerable network and may be functionally impaired even when not directly mutated.[5:1][6:1]
Synaptic decline in Alzheimer's Disease includes altered levels of presynaptic proteins involved in vesicle priming and fusion. Complexin-1 changes are interpreted as indicators of failing release homeostasis, especially in hippocampal and cortical pathways.[4:2][9]
In Amyotrophic Lateral Sclerosis, cortical and spinal synaptic dysfunction precedes extensive neuronal death. CPLX1-related release dysregulation likely contributes to impaired motor-network stability and reduced adaptive plasticity.[6:2][10]
Complexin-1 is mainly a mechanistic marker and experimental target rather than a current direct therapeutic target. Useful translational roles include:
Interventions that improve vesicle priming, stabilize SNARE interactions, or reduce proteostasis stress may indirectly normalize complexin-dependent release behavior.[3:3][4:3]
The study of Complexin 1 Protein (Cplx1) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Reim K, Wegmeyer H, Brandstatter JH, et al. Structurally and functionally unique complexins at retinal ribbon synapses. Cell. 2005. ↩︎ ↩︎ ↩︎
Xue M, Reim K, Chen X, et al. Distinct domains of complexin I differentially regulate neurotransmitter release. Nat Struct Mol Biol. 2007. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Rizo J, Rosen MK. Synaptic vesicle fusion. Annu Rev Cell Dev Biol. 2008. ↩︎ ↩︎ ↩︎ ↩︎
Selkoe DJ. Alzheimer disease is a synaptic failure. Science. 2002. ↩︎ ↩︎ ↩︎ ↩︎
Bridi JC, Hirth F. Mechanisms of alpha-synuclein induced synaptopathy in Parkinson disease. Front Neurosci. 2018. ↩︎ ↩︎
Fogarty MJ. Driven to decay synaptic dysfunction in amyotrophic lateral sclerosis. Neural Regen Res. 2019. ↩︎ ↩︎ ↩︎
Kaeser-Woo YJ, Yang X, Sudhof TC. C-terminal complexin sequence is selectively required for clamping but not priming of synaptic exocytosis. Neuron. 2012. ↩︎
McMahon HT, Missler M, Li C, Sudhof TC. Complexins have a critical role in neurotransmitter secretion. Cell. 1995. ↩︎
de Wilde MC, Overk CR, Sijben JW, et al. Meta-analysis of synaptic pathology in Alzheimer disease reveals selective molecular vulnerability. Mol Neurodegener. 2016. ↩︎
Sleigh JN, Rossor AM, Fellows AD, et al. Axonal transport and neurological disease. Nat Rev Neurol. 2014. ↩︎